Fig. 2: Descartes-08 can be manufactured at scale with attractive T cell pharmacology and phenotypes. | Nature Medicine

Fig. 2: Descartes-08 can be manufactured at scale with attractive T cell pharmacology and phenotypes.

From: BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

Fig. 2

a, Schematic of the phase 2b, placebo-controlled RCT in patients with generalized MG. b–d, Graphs showing frequencies of DC-08 viability (b) measured by fluorescence microscopy and CD8 expression (c) or anti-BCMA CAR expression (d) measured by flow cytometry on lots of DC-08 produced for the RCT (n = 35). e, Graph showing the characterization of CD8+ T cell subsets in DC-08 lots characterized by flow cytometry, including TSCM, TCM, TEM, TTE and TEX subsets (n = 35). f, Quantitation of DC-08 mRNA in circulation of whole blood at indicated days (screen (SCR), day 1, month 1 and month 3) at pre-infusion (pre) or 30 minutes post-infusion (post) timepoints for participants randomized to the active DC-08 cohort (n = 19). Dotted line indicates LLOQ. Box-and-whisker plots show the median, interquartile range and full range of data, along with individual data points. Source data are provided for this figure. Panel a created with BioRender.com.

Source data

Back to article page